Inhibition of cyclin-dependent kinase 1 (CDK1) by phosphorylation is a key regulatory mechanism for both the unperturbed cell cycle and the DNA damage checkpoint. Although both WEE1 and MYT1 can phosphorylate CDK1, little is known about the contribution of MYT1. We found that in contrast to WEE1, MYT1 was not important for the normal cell cycle or checkpoint activation. Time-lapse microscopy indicated that MYT1 did, however, have a rate-determining role during checkpoint recovery. Depletion of MYT1 induced precocious mitotic entry when the checkpoint was abrogated with inhibitors of either CHK1 or WEE1, indicating that MYT1 contributes to checkpoint recovery independently of WEE1. The acceleration of checkpoint recovery in MYT1-depleted cells was due to a lowering of threshold for CDK1 activation. The kinase activity of MYT1 was high during checkpoint activation and reduced during checkpoint recovery. Importantly, although depletion of MYT1 alone did not affect longterm cell growth, it potentiated with DNA damage to inhibit cell growth in clonogenic survival and tumor xenograft models. These results reveal the functions of MYT1 in checkpoint recovery and highlight the potential of MYT1 as a target for anti-cancer therapies.
INTRODUCTION
Cyclin-dependent kinase 1 (CDK1) is one of the major kinases for driving cells into mitosis. Its activation requires the binding of cyclin B and the phosphorylation of the T-loop. Cyclin B starts to accumulate from S phase and is destroyed at the end of mitosis. 1 Before mitosis, cyclin B-CDK1 complexes are inactivated through phosphorylation of Thr14 and Tyr15 by WEE1 and MYT1. 2, 3 While WEE1 specifically phosphorylates Tyr15, MYT1 shows a preference for Thr14.
Just before mitosis, WEE1 and MYT1 are downregulated to allow CDK1 activation. The NH2-terminal region of WEE1 is phosphorylated by CDK1, PLK1 and CK2, creating a phosphodegron for SCF bTrCP -dependent degradation. [4] [5] [6] Any residual WEE1 is also inhibited by CDK1-and AKT/PKB-dependent phosphorylation as well as by binding to PIN1. 7 By contrast, relatively little is known about how MYT1 is inactivated. In mammalian cells, the inactivation of MYT1 coincides with its phosphorylation by PLK1 and CDK1. 2, 8, 9 WEE1 has an indispensable role in controlling the timing of mitosis during normal cell cycle. Depletion of WEE1 resulted in premature chromosome condensation. 10 By contrast, MYT1 appears to have a relatively minor role in the somatic cell cycle. 11 As MYT1 is the only CDK1 inhibitory kinase in prophasearrested Xenopus oocytes, MYT1 is believed to have an important role in the meiotic cycle during early development. 12 Under this condition, MYT1 is inactivated by XRINGO-and CDK-mediated phosphorylation. 13 In starfish, MYT1 activity is downregulated by AKT-dependent phosphorylation during meiosis. 14 Proper cell cycle progression requires several checkpoints that regulate the activities of CDKs. The G 2 DNA damage checkpoint exerts its effect mainly through the inhibitory phosphorylation of CDK1. Upon DNA damage, ATM/ATR phosphorylates and activates CHK1/CHK2, which in turn inactivates CDC25 (reviewed in Chen and Poon 15 ). This response tips the balance of the CDK1 Thr14/ Tyr15 phosphorylation toward inactivation of the kinase. Indeed, the checkpoint induced by ionizing radiation (IR) can be abrogated by overexpressing a non-phosphorylatable CDK1 mutant. 16 Once damaged DNA is repaired, the checkpoint has to be switched off to restart the cell cycle. This requires CDC25B, but not CDC25A and CDC25C, indicating a divergence of the roles of cell cycle components in checkpoint recovery and unperturbed cell cycle. 4 Similarly, although PLK1 is not required for normal mitotic entry, it is important for checkpoint recovery. 4 While WEE1 is known to have an important role in the G 2 DNA damage checkpoint, 17 next to nothing is known about the function of MYT1 in the checkpoint.
In this study, we have investigated the functions of MYT1 in checkpoint recovery. We found that while MYT1 was not essential for the unperturbed cell cycle or the activation of the DNA damage checkpoint, it had a rate-determining function in checkpoint recovery. Downregulation of MYT1 also promoted DNA damagemediated cytotoxicity in cell line and nude mice models.
RESULTS

MYT1
is not involved in the control of the unperturbed cell cycle and activation of the G 2 DNA damage checkpoint We started by analyzing the temporal expression pattern of MYT1 in HeLa cells. Cells were released from a double thymidine synchronization procedure and harvested every 3 h. Mitosis occurred at between 9-12 h, as indicated by the DNA contents and the expression of phosphos-CDK Tyr15 and mitotic cyclins ( Figure 1a ). While the expression of WEE1 decreased during mitosis, MYT1 displayed a dramatic gel mobility shift. Addition of the proteasome inhibitor MG132 stabilized WEE1 and cyclin A2 without affecting MYT1 (Supplementary Figure S1A) , verifying that MYT1 was not regulated by degradation. The disappearance of the slower-migrating form of MYT1 after lambda phosphatase treatment verified that MYT1 was strongly phosphorylated during mitosis (Figure 1b) . 9 Figure 1. MYT1 is not important for the unperturbed cell cycle. (a) Level and phosphorylation of MYT1 during the cell cycle. HeLa cells were synchronized with a double thymidine block method. At different time points after released from the block, the cells were harvested and analyzed with flow cytometry (the positions of 2N and 4N DNA contents are indicated). Lysates were also prepared and the expression of the indicated proteins was analyzed with immunoblotting. Uniform loading of lysates was confirmed by immunoblotting for actin. The positions of the phosphorylated and unmodified MYT1 are indicated. (b) Gel mobility shift of MYT1 during mitosis is phosphorylation-dependent. MYT1 was immunoprecipitated from mitotic cell extracts (from cells collected at 12 h after release from double thymidine block as described in panel a). The immunoprecipitates were treated with either buffer or lPPase. The gel mobility of MYT1 was then analyzed with immunoblotting. (c) MYT1 is not required for the activation of various checkpoints. HeLa cells were either mock-transfected or transfected with siRNA against MYT1 (siMYT1). After 48 h, the cells were treated with hydroxyurea (HU), IR or nocodazole (NOC) for 16 h. Lysates were then prepared and the expression of the indicated proteins was analyzed with immunoblotting. Equal loading of lysates was confirmed by immunoblotting for actin. To study the functions of MYT1, we depleted MYT1 with small interfering RNAs (siRNAs) (siMYT1) and verified the depletion with immunoblotting ( Figure 1c ). This resulted in negligible effects on normal cell cycle distribution (Figure 1d ). MYT1-depleted cells were able to be trapped by hydroxyurea, IR or nocodazole in S phase, G 2 phase or mitosis, respectively, indicating that the proper activation of the various checkpoints did not require MYT1. Timelapse microscopy also confirmed DNA damage was able to induce a cell cycle arrest in MYT1-depleted cells (see below).
WEE1 prevents premature activation of cyclin-CDK1 complexes during G 2 phase. To evaluate the possible contribution of MYT1 on the timing of mitosis, cells expressing histone H2B-GFP were generated and transfected with siMYT1. After they were synchronously released from a double thymidine block, individual cells were then tracked with time-lapse microscopy to monitor the timing of mitosis (Supplementary Figure S2) . The average time taken for the control cells to enter mitosis was B600 min (Figure 1e ). This period was dramatically reduced to B300 min when WEE1 was downregulated with siRNA. In contrast, MYT1-depleted cells entered mitosis at a similar time as control cells. PLK1 is implicated to have a role in mitotic entry. 18 Interestingly, depletion of PLK1 (either alone or together with MYT1) did not affect the timing of mitotic entry (Figure 1e ). Instead, knockdown of PLK1 abolished mitotic exit, resulting in a very protracted mitosis (Supplementary Figure S2) . Taken together, these results indicate that unlike that for WEE1, there is no evidence that MYT1 has a role in the timing of mitosis during the unperturbed cell cycle of HeLa cells.
MYT1 is a component of the checkpoint recovery network Several potential cell cycle regulators including PLK1 and CDC25B appear to be non-essential for normal G 2 -M transition, yet have important roles during the recovery of the G 2 DNA damage checkpoint. 19 To determine whether MYT1 is involved in checkpoint recovery, siMYT1 was transfected before DNA damage was introduced with IR. HeLa cells were used as a model because IR exclusively activated the G 2 DNA damage checkpoint in these cells (p53 is degraded by HPV E6). We used a CHK1 inhibitor (UCN-01) to turn off the checkpoint, thereby mimicking checkpoint recovery and inducing mitosis synchronously in the population. 20 Time-lapse microscopy confirmed that almost no cell underwent mitosis after IR treatment (Supplementary Figure S3A) . Moreover, MYT1 depletion did not affect the IR-mediated cell cycle arrest over the imaging period (Supplementary Figure S3B) . Addition of UCN-01 stimulated mitosis (Figure 2a, Supplementary Figure S4 ). While mitotic entry occurred at B250 min in control cells, it was shortened by 50 min in MYT1-depleted cells. As a positive control, depletion of PLK1 significantly delayed mitotic entry during checkpoint (Figure 2a) . Interestingly, the delay caused by PLK1 depletion was reversed by co-depletion of MYT1, suggesting a downstream role of MYT1.
Checkpoint-abrogated cells frequently underwent cell death during mitosis. Alternatively, some cells were able to complete the mitosis (albeit frequently with cytokinesis failure), then either survived or died (postmitotic cell death) in the following interphase. 20 We found that siMYT1 increased mitotic cell death following checkpoint abrogation (Figure 2b ). By the end of the imaging period (22 h after UCN-01 treatment), only 20% of MYT1-depleted cells remained (compare with over 40% in the control). As siMYT1 alone was not cytotoxic (Supplementary Figure S2C) , the increase in mitotic cell death was likely to be caused by the shortening of mitotic entry time after checkpoint abrogation.
The premature checkpoint recovery in MYT1-depleted cells was further verified using flow cytometry ( Figure 3a ). As expected, IR treatment arrested cells with DNA contents corresponding to G 2 /M phase. Bypass of the checkpoint with UCN-01 promoted the appearance of G 1 cells. This was further accelerated in MYT1-depleted cells and delayed in PLK1-depleted cells. The sub-G 1 population in PLK1-depleted cells was consistent with the extensive mitotic cell death observed using time-lapse microscopy (Supplementary Figure S4) .
To examine the accumulation of the mitotic markers during checkpoint recovery, nocodazole was added together with UCN-01 to prevent checkpoint-abrogated cells from exiting mitosis. The fact that depletion of MYT1 promoted checkpoint recovery was supported by the premature accumulation of phospho-histone H3 Ser10 and disappearance of phospho-CDK1 Tyr15 ( Figure 3b ). Notably, the absence of MYT1 resulted in a lower level of CDK1 Tyr15 phosphorylation during checkpoint activation (see later). As a control, PLK1 depletion delayed CDK1
Tyr15 dephosphorylation and histone H3 Ser10 phosphorylation. We next repeated the checkpoint recovery experiments with a siRNA that targeted a different region of MYT1 (Supplementary Figure S5) . Entry into mitosis after checkpoint abrogation was also speeded up by the second siMYT1, supporting the specificity of the effects of MYT1 knockdown. To exclude the possibility that the function of MYT1 is only limited to HeLa cells, we also demonstrated similarly accelerated mitotic entry following checkpoint abrogation in MYT1-depleted U2OS cells (Supplementary Figure S6) . Interestingly, while depletion of PLK1 delayed mitosis, it was not reversed by the co-depletion of MYT1, suggesting that PLK1 probably have multiple targets during checkpoint recovery in U2OS cells. Finally, we performed the converse experiment by overexpressing MYT1. As expected, the mitotic entry time after checkpoint abrogation was significantly delayed after MYT1 overexpression (Supplementary Figure S7) .
Taken together, our results indicate that although MYT1 is not essential for normal cell cycle and arrest following DNA damage, it has a rate-determining role for the recovery of the G 2 DNA damage checkpoint.
MYT1 and WEE1 contributes independently to checkpoint recovery As UCN-01 inhibited upstream activators for both MYT1 and WEE1, we next investigated the contribution of MYT1 and WEE1 more directly with a specific WEE1 inhibitor MK1775. 21 Inhibition of WEE1 was sufficient to induce checkpoint abrogation ( Figure 4a MYT1 is involved in setting a threshold for CDK1 activation during checkpoint recovery To understand how MYT1 affects checkpoint recovery, we first excluded the possibility that the degree of DNA damage was actually affected by MYT1. Similar number of g-H2AX foci was found after IR treatment in control, MYT1-or PLK1-depleted cells (Figure 5a ), suggesting that the extent of DNA damage was not affected by MYT1 depletion.
Given that CDK1 Tyr15 phosphorylation appears to be compromised in MYT1-depleted cells (Figure 3b) , we next examined the activity of CDK1. As a control, knockdown of WEE1 uncoupled the DNA damage checkpoint, resulting in CDK1 Tyr15 dephosphorylation and histone H3 Ser10 phosphorylation (Figure 5b) . Indeed, the kinase activity of CDK1 was substantially increased after WEE1 depletion ( Figure 5c ). Although histone H3 Ser10 phosphorylation did not increase in MYT1-depleted cells (indicating that the checkpoint was not bypassed), there was a two-fold increase in CDK1 kinase activity over control-irradiated cells. This was not due to a change in the total level of cyclin B1 (Figure 5b ). This was also supported by the similar maximum CDK1 activity attained when cyclin B1-CDK1 complexes were completely activated with recombinant CDC25A (Figure 5c ). During checkpoint recovery, although the CDK1 activity reached similar maximum levels in the presence or absence of MYT1, it reached a higher level faster after MYT1 depletion (Figure 5d ). This may provide a molecular explanation on the faster checkpoint recovery in the absent of MYT1.
Collectively, these results indicate that the acceleration of checkpoint recovery in MYT1-depleted cells is not due to a difference in the extent of DNA damage, but is likely to be caused by a decrease in CDK1 inhibitory phosphorylation during checkpoint activation, with a consequent faster activation of CDK1 during recovery.
Depletion of MYT1 potentiates with DNA damage to inhibit tumor growth in mouse xenograft models Given that MYT1-depeleted cells underwent premature checkpoint recovery after DNA damage, we next examined their long-term growth potential (Figure 6a) . Unlike siWEE1 or siPLK1, siMYT1 alone did not affect clonogenic survival. When combined with IR treatment, however, siMYT1 exerted a pronounced effect on survival. Hence although MYT1 is not required for the immediate cell cycle arrest after DNA damage (up to 36 h, see above), it is important for maintaining long-term cell survival after DNA damage.
We further tested the growth of MYT1-depleted cells with nude mouse xenograft models. Initially, we treated siMYT1-transfected HeLa cells with IR in vitro before injecting them subcutaneously into nude mice. When the cells were not treated with IR, no significant difference in the increase in tumor volume was found between control and siMYT1-transfected cells (Figure 6b ). When IR was delivered, however, tumor growth was significantly delayed in siMYT1-transfected cells (Figure 6c) .
We next performed experiments in which the cells were first injected into the nude mice before IR was delivered in vivo. Lysates were subjected to immunoprecipitation with antibodies against CDK1. The immunoprecipitates were then incubated with either buffer or purified GST-CDC25A as described in Materials and Methods. The kinase activity was then assayed using histone H1 as a substrate. Phosphorylation was quantified with a PhosphorImager (mean ± s.d. of three independent experiments). (d) Full activation of CDK1 after checkpoint abrogation is achieved earlier in MYT1-depleted cells. HeLa cells were transfected with either control or siMYT1. After 24 h, the cells were treated with IR and incubated for another 16 h. The cells were then treated with UCN-01 and harvested at the indicated time points. Lysates were subjected to immunoprecipitation with antibodies against CDK1. The kinase activity was then assayed using histone H1 as a substrate. Phosphorylation was quantified with a PhosphorImager (mean ± s.d. of three independent experiments).
After irradiation, the growth of siMYT1-transfected cells was reduced pronouncedly (Figure 6d) . The results were confirmed using a second siRNA to downregulate MYT1 (Supplementary Figure S8) . Collectively, these results indicate that although MYT1 depletion alone does not affect long-term cell growth, it potentiates with DNA damage to inhibit growth in cell culture and xenograft models.
MYT1 is inactivated during checkpoint recovery
Given the importance of MYT1 in checkpoint recovery, we next investigated whether the activity of MYT1 is regulated during the process. We developed an MYT1 kinase assay using cyclin B1-CDK1 complexes as substrates. As MYT1 is a membrane-associated protein kinase, its activity cannot be easily assayed using standard immunoprecipitation. The fact that WEE1 and MYT1 are located in different cellular compartments enabled us to separate them using fractionation (Figure 7a) . MYT1 was present in the membrane fraction but not in the cytosol and nuclear fraction. Conversely, WEE1 was detected only in the cytosol and nuclear fraction. Cyclin B1-CDK1 complexes were immunoprecipitated from mitotic cell extracts and eluted with FLAG peptides (the cyclin B1 is FLAG-tagged) to serve as a substrate for WEE1 and MYT1. As WEE1 and MYT1 are believed to be regulated by CDK1, we first incubated the cyclin B1-CDK1 complexes with a specific CDK1 inhibitor RO3306 (Supplemenatry Figure S9A) . To assay the activity of MYT1, the RO3306-inhibited cyclin B1-CDK1 complexes were incubated with the MYT1 fraction. Phosphorylation of CDK1 by MYT1 was detected by using either radiolabelled ATP or immunoblotting. As expected, MYT1 kinase activity was active during IR-mediated G 2 DNA damage checkpoint and reduced during mitosis (Figure 7b) . Furthermore, the MYT1 activity could be abolished by incubation with recombinant PLK1 (Figure 7c ), supporting the idea that PLK1 is a negative regulator of MYT1. 9 The MYT1-dependent phosphorylation of CDK1 was confirmed by using phospho-CDK1 Thr14 antibodies (Figure 7d) . Importantly, the CDK1 Thr14 phosphorylation was significantly reduced when MYT1 was first downregulated with siMYT1, indicating the specificity of the kinase assay for MYT1. As a control, mixing of the cyclin B1-CDK1 substrate with the membrane fractions without incubation resulted in a very low background of CDK1 Thr14 phosphorylation, indicating that both the MYT1 fractions and CDK1 substrates contained only low basal CDK1 Thr14 phosphorylation (Supplementary Figure S9B) .
The relatively high MYT1 kinase activity after DNA damage was reduced after incubation with UCN-01, indicating that MYT1 was inactivated during checkpoint recovery (Figures 7b and e) . This was not simply due to a reduction in the total level of MYT1 (Figure 7f) . Finally, we found that the activity of exogenously expressed FLAG-tagged MYT1 was similarly reduced during checkpoint recovery (Supplementary Figure S9C) . Collectively, these data indicate that MYT1 was turned off during checkpoint recovery, supporting the hypothesis that MYT1 has an important role in the process.
DISCUSSION
Inhibitory phosphorylation of CDK1 is now firmly established as a key mechanism for normal cell cycle control as well as during DNA damage and replication checkpoints. Recently, we found that inhibitory phosphorylation of CDK1 may also have a role in mitotic exit, in particular when the degradation of the mitotic cyclins is compromised. 22 The available evidence suggests that WEE1 has an indispensable role in regulating CDK1. For example, while the Mitotic cells were also collected after treatment with nocodazole for 16 h. Membrane fractions containing MYT1 were isolated as described in Materials and Methods and incubated with or without lPPase. MYT1 was detected with immunoblotting. As multiple phosphorylated forms of MYT1 were present, the lPPase treatment allowed a more accurate comparison of MYT1 expression in different samples.
expression of the non-phosphorylatable mutant of CDK1 Tyr15 induces premature mitotic events, a similar mutant of CDK1 Thr14 (a site phosphorylated by MYT1, but not WEE1) does not induce premature mitosis. 23 In agreement with a major role of WEE1 in CDK1 regulation, expression of siWEE1 induced premature mitosis ( Figure 1e ) followed by massive cell death (Supplementary Figure S2) . The DNA damage checkpoint was also abrogated by either siWEE1 or the WEE1 inhibitor MK1775, leading to precocious activation of CDK1 (Figure 5c ), CDK1
Tyr15 dephosphorylation and histone H3 Ser10 phosphorylation (Figure 5b ), mitotic entry ( Figure 4a ) and cell death (Figures 4a and 6a) . By contrast, the contribution of MYT1 to cell cycle control appears to be relatively minor. Depletion of MYT1 affected neither the cell cycle distribution (Figure 1d ) nor the timing of mitosis (Figure 1e,  Supplementary Figure S2) .
The absence of MYT1 also did not have a strong impact on the activation of the DNA damage checkpoint. MYT1-depleted cells were able to arrest in G 2 phase after irradiation, as indicated by flow cytometry (Figure 1d ) or time-lapse microscopy (Supplementary Figure S3) . Our results differ from a report that indicates that Adriamycin-induced G 2 arrest in HeLa cells is abrogated when MYT1 is downregulated. 24 Nevertheless, we found that downregulation of MYT1 did have a significant impact on the effectiveness of the G 2 DNA damage checkpoint. IRinduced Thr14/Tyr15 phosphorylation was reduced after MYT1 was downregulated (Figures 1c and 3b) . Consistently, the kinase activity of CDK1 after DNA damage was slightly increased after MYT1 depletion (Figure 5c ). Although effective depletion of MYT1 by the siRNAs was generally observed (for example, Figures 1c and  3b and Supplementary Figure S5C) , depletion was likely to be incomplete. Indeed, residual MYT1 kinase activity could be detected in vitro after siMYT1 transfection (Figure 7d ). But importantly, such downregulation of MYT1 was able to reduce the long-term survival of irradiated cells, as indicated by clonogenic assays (Figure 6a ) and growth in nude mice (Figures 6c and d) .
Conceptually, the checkpoint is inactivated once the damaged DNA is repaired, allowing the cell cycle to resume. To study checkpoint recovery in the entire population, chemicals that abrogated the checkpoint, including inhibitors of CHK1 (UCN-01) and WEE1 (MK1775) were generally used. While these models have their limitations, they enable us to study checkpoint recovery synchronously, without being affected by the heterogeneity of individual cells with different levels of DNA damage. Using these models, we found that depletion of MYT1 induced precocious entry into mitosis during checkpoint recovery. We demonstrated this using time-lapse microscopy ( Figure 2 ), flow cytometry (Figure 3a) , immunoblotting of mitotic markers (Figure 3b ) and CDK1 kinase activity (Figure 5d ). The conclusion was further substantiated using another siMYT1 (Supplementary Figure S5) as well as a different cell line (Supplementary Figure S6) . Moreover, depletion of MYT1 also accelerated mitotic entry when the checkpoint was abrogated with MK1775 (Figure 4 ), indicating that MYT1 had an independent role from WEE1. The model depicted in Figure 8 illustrates the role of MYT1 in checkpoint recovery.
The underlying mechanism of the accelerated checkpoint recovery in MYT1-depleted cells is likely to be due to the lowering of threshold for CDK1 activation. MYT1 depletion reduced CDK1 inhibitory phosphorylation (Figures 1c and 3b ) and increased CDK1 kinase activity (Figure 5c ) after DNA damage. Although sufficient to affect checkpoint recovery, the lowering of CDK1 inhibitory phosphorylation was clearly unable to promote mitosis during checkpoint activation (at least for the first 36 h after DNA damage, Supplementary Figure S3 ). In contrast, targeting WEE1 triggered mitosis immediately (Figure 4) , confirming WEE1 had a more central role in keeping CDK1 inactive during checkpoint activation. The precocious checkpoint recovery after the downregulation of MYT1 is likely to undermine effective DNA repair, leading to a significant impact on long-term survival ( Figure 6 ). In this connection, it would be interesting to examine the role of MYT1 in checkpoint recovery in the absence of checkpointbypassing agents such as UCN-01 or MK1775. However, these types of analysis are difficult due to the large variation of the time required for checkpoint recovery (or repair) between individual cells.
It is known that PLK1 has an important role in checkpoint recovery. 4 Indeed, we confirmed that depletion of PLK1 significantly delayed mitotic entry during checkpoint recovery. Interestingly, mitotic entry time was shortened when PLK1 and MYT1 were co-depleted, suggesting that MYT1 is downstream of PLK1 in the checkpoint recovery pathway (Figures 2 and 3 ). This is consistent with studies indicating that PLK1 can phosphorylate the C-terminus of MYT1. 9 In agreement with these, we found that MYT1 was activated during checkpoint activation and inactivated during checkpoint recovery (Figures 7b and e) . Furthermore, MYT1 isolated from checkpoint-activated cells could be inhibited by PLK1 in vitro (Figure 7c ).
DNA damage followed by checkpoint abrogation has been developed as a strategy for anti-cancer therapies. Forcing damaged cells into premature mitosis frequently triggers cell death through mitotic catastrophe. However, some checkpointabrogated cells can remain viable and progress into G 1 phase, which may contribute to further genome instability. Our previous studies reveal that the extent of DNA damage and the effectiveness of the spindle-assembly checkpoint are pivotal determinants of mitotic catastrophe after checkpoint abrogation. 20 In this study, we found that downregulation of MYT1 shortened the time between checkpoint abrogation and mitotic entry. Importantly, this also increased the level of subsequent cell death (Figure 2b ). An implication of these results is that MYT1 may be a useful target for anti-cancer therapies. In agreement with this, combined treatments with IR and siMYT1 reduced tumor growth Figure 8 . MYT1 is involved in checkpoint recovery. The G 2 DNA damage checkpoint maintains CDK1 in a Thr14-and Tyr15-phosphorylated, inactive state. This is achieved through the combined action of the activation of WEE1 and inhibition of the CDC25 family. In this study, we show that although MYT1 is not essential for checkpoint activation, it does contribute to the levels CDK1 inhibitory phosphorylation attained during checkpoint activation. During checkpoint recovery, the signals from the ATM/ ATR-CHK1/CHK2 pathway are removed. CDC25 is activated and WEE1 inhibited (in part through regulation by PLK1) to allow dephosphorylation and activation of CDK1. We found that MYT1 is also inactivated during checkpoint recovery, possibly also dependent on PLK1. Downregulation of MYT1 accelerates checkpoint recovery and mitotic entry.
in xenograft models (Figure 6 ). MYT1 is a particularly attractive target because it is not required for normal cell cycle progression (Figure 1) . Cell cycle components that are essential for normal cell cycle progression (for example, WEE1 or PLK1) may be too toxic for normal cells and unsuitable for use in therapies.
In conclusion, downregulation of MYT1 reduces the inhibitory phosphorylation of CDK1 during checkpoint activation. This leads to precocious mitotic entry during checkpoint recovery and increase of cytotoxicity after checkpoint abrogation. These data underscore the function of MYT1 in checkpoint recovery and implicate MYT1 as a potential target for anti-cancer therapies.
MATERIALS AND METHODS Materials
All reagents were obtained from Sigma-Aldrich (St. Louis, MO, USA) unless stated otherwise.
Cell culture and cell growth analysis
The HeLa cell line used in this study was a clone that expressed the Tet repressor. 25 HeLa 26 and U2OS 20 expressing histone H2B-GFP and HeLa cells expressing FLAG-cyclin B1 27 were generated as previously described. Cells were propagated in DMEM supplemented with 10%(v/v) calf serum (for HeLa) or fetal bovine serum (for U2OS) (Invitrogen, Carlsbad, CA, USA) and 50 U/ml penicillin-streptomycin (Invitrogen) in a humidified incubator at 37 1C in 5% CO 2 . Unless stated otherwise, cells were treated with the following reagents at the final concentration: hydroxyurea (1.5 mM), MG132 (10 mM), MK1775 (100 nM), nocodazole (0.1 mg/ml) and UCN-01 (100 nM). Double thymidine synchronization, 22 trypan blue analyses 28 and clonogenic survival assays 29 were performed as previously described.
DNA constructs 0 -GTTAAAAGTGCAGAGGCAGAGTCGGA TCCTCAGG-3 0 using myc-MYT1 in pcDNA3 (a gift from Helen PiwnicaWorms) as a template; 30 the PCR fragment was partially digested with Nco I and BamH I and ligated into pUHD-P3T 31 to generate FLAG-MYT1 in pUHD-P3T. To construct GST-PLK1, PLK1 was amplified by PCR with 5 0 -G CTGAATTCGCATGAGTGCTGCAG-3 0 and 5 0 -GGGCTCGAGTTAGGAGGCCTTG AG-3 0 using myc-PLK1 in pRcCMV (a gift from Katsumi Yamashita) as a template; the PCR product was digested with EcoR I and Xho I and ligated into pGEX-KG. GST-CDC25A was described previously. 32 
RNA interference
Stealth siRNAs targeting WEE1 (5 0 -CCUCAGGACAGUGUCGUCGUAGAAA-3 0 ) and PLK1 (5 0 -CAGCCUGCAGUACAUAGAGCGUGAU-3 0 ) were obtained from Invitrogen. Two siRNAs targeting MYT1 (5 0 -CCUGGAUUCUCCCUCAAGAT T-3 0 and 5 0 -GUGACAUCAACUCAGAGCCTT-3 0 ) were obtained from RibioBio (Guangzhou, China). Unless stated otherwise, the first MYT1 siRNA was used. Cells were transfected with siRNA using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instructions.
Ionizing radiation IR was delivered as described previously. 29 Live-cell imaging Cells were seeded onto 24-well plates and imaged as described previously. 29 Data acquisition was carried out at 5 min per frame.
Flow cytometry
Flow cytometry analysis after propidium iodide staining was performed as described previously. 28 
Fractionation
HeLa cells growing on 100-mm plates were washed with 10 ml of PBS and harvested by a cell scraper in 1 ml of PBS. The cells were collected by centrifugation at 5000 r.p.m. for 150 s. The pellet were resuspended in 500 ml of lysis buffer (10 mM PIPES pH 7.4, 10 mM KCl, 2 mM MgCl 2 , 1 mM DTT) and incubated on ice for 15 min. The cells were passed through a 25G syringe with 15 strokes. After centrifugation at 4 1C at 3200 r.p.m. for 5 min, the pellet was collected as the nuclear fraction. The supernatant was centrifuged again at 41C at 14 000 r.p.m. for 10 min. The supernatant and pellet were collected as the cytosol and membrane fractions, respectively.
Antibodies and immunological methods
Monoclonal antibodies against b-actin, 33 cyclin A2 34 and cyclin B1 26 were obtained from sources as described previously. Polyclonal antibodies against gH2AX (Upstate Biotechnology Lake Placid, NY, USA), phospho-CDK1 Thr14 (Abcam, Cambridge, UK), phospho-CDK1 Tyr15 , phospho-CDK1
Thr161
(Cell Signaling Technology, Beverly, MA, USA), phospho-histone H3 Ser10 , PLK1 and MYT1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were obtained from the indicated suppliers. Monoclonal antibodies against CDC25C, cyclin E and WEE1 were obtained from Santa Cruz Biotechnology. Immunoblotting and immunoprecipitation were performed as described. 35 Cells were prepared for immunofluorescence microscopy as previously described. 20 Kinase and phosphatase assays
The expression (in bacteria) and purification of GST-CDC25A and GST-PLK1 with glutathione-agarose chromatography were as described previously. 35 For treatment with GST-CDC25A, immunoprecipitates were incubated with 1 mg of GST-CDC25A in 10 ml of buffer A (10 mM HEPES pH 7.2, 25 mM KCl, 10 mM NaCl, 1.1 mM MgCl 2 , 0.1 mM EDTA, 0.1 mM DTT) at 25 1C for 30 min. After washing in kinase buffer, the histone H1 kinase activity was assayed as described previously. 35 Phosphorylation was quantified with a PhosphorImager (Bio-Rad, Hercules, CA, USA). To assay MYT1 activity, HeLa cells stably expressing FLAG-cyclin B1 were treated with nocodazole for 16 h before harvested by mechanical shake-off. Lysates were prepared and 300 mg was subjected to immunoprecipitation using beads conjugated with anti-FLAG antibodies. The FLAG-cyclin B1-CDK1 complexes were eluted by incubation with 0.2 mg of FLAG peptides in 10 ml of buffer A. The eluent was incubated with the membrane fraction in 50 ml of MYT1 kinase buffer (50 mM Tris-Cl pH 8.0, 10 mM MgCl 2 , 50mM ATP, 1 mM DTT) supplemented with 0.2 ml of (g-32 P)-ATP (for radioactive assay) and 10 mM of RO3306 at 30 1C for 1 h. For PLK1 treatment, the membrane fractions were incubated with 1 mg of GST or GST-PLK1 in 20 ml of MYT1 kinase buffer at 25 1C for 30 min. For lPPase treatments, immunoprecipitates or membrane fractions were washed once with buffer (50 mM HEPES pH 7.5, 2 mM MnCl 2 , 100 mM EGTA, 5 mM DTT and 0.01% BRIJ-35) and incubated with 400 U of lPPase in 10 ml of buffer at 301C for 1 h.
Tumor xenografts
The experimental protocol was evaluated and approved by the Animal Care Committee, HKUST. HeLa cells (2 Â 10 6 ) were injected subcutaneously into both sides of the dorsa of 4-8 week-old female BALB/c nude mice. Three animals per group were used in each experiment. Tumors were regularly measured using a Vernier caliper. Volume was calculated according to the formula: p/6 Â length Â width 2 . 36 Mice were killed when tumors reached 1000 mm 3 .
